NASDAQ Composite ended the session with Arcturus Therapeutics rising 4.37% to $38.24 on Wednesday, after two successive sessions in a row of losses. NASDAQ Composite rose 1.19% to $13,950.22, after two successive sessions in a row of losses, on what was an all-around positive trend exchanging session today.
Arcturus Therapeutics today’s close was $38.24, 239.20% below its 52-week high of $129.71.
Arcturus Therapeutics’s Sales
Arcturus Therapeutics’s sales growth is a negative 4% for the ongoing quarter and a decline by 28% for the next. The company’s growth estimates for the present quarter and the next is a negative 86.6% and a negative 163.6%, respectively.
Arcturus Therapeutics’s Revenue
Year-on-year quarterly revenue growth declined by 24.6%, now sitting on 9.54M for the twelve trailing months.
Arcturus Therapeutics’s last day, last week, and last month’s current volatility was 0.74%, 2.85%, and 3.67%, respectively.
Arcturus Therapeutics‘s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.87% (day), 7.06% (last week), and 7.32% (last month), respectively.
Arcturus Therapeutics’s Stock Yearly Top and Bottom Value
Arcturus Therapeutics’s stock is valued at $38.24 at 17:15 EST, way under its 52-week high of $129.71 and way above its 52-week low of $13.09.
Arcturus Therapeutics’s Moving Average
Arcturus Therapeutics’s worth is way below its 50-day moving average of $50.01 and way below its 200-day moving average of $62.10.
More news about Arcturus Therapeutics.